Indian's leading biotech group Biocon closes fiscal 2013 on a very strong note. "The key contributors to growth this fis cal have been Research Services, Branded Formulations and our growing biosimilar business, led by generic insulins. Biocon's insulin franchise continues to garner market share across India and emerging markets and now accounts for more than 10 percent of our sales. This quarter saw us enhance our partnership with Mylan through the re-licensing of our portfolio of generic insulin analogs. The partnership with Mylan endorses the intrinsic value of this asset and significantly reduces our burden of development costs involved in global commercialization," said chairman and managing director, Dr Kiran Mazumdar-Shaw.
FY2013 revenues at Rs 2,538 crore; EBITDA at Rs 596 crore; PAT at Rs 509 crore
Performance financial highlights:
Sales breakup for Q4: